NDA 220711 · Beone Medicines USA
Beqalzi
Sonrotoclax · Oral
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanCDER novel approval, May 13, 2026: To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor
Last checked: Nov 20, 2026Latest source record: May 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
May 13, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
53
6 Phase 3, 21 recruiting
FAERS reports
16
15 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 25, 2026.
BEQALZI is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor. This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) [see Clinical Studies (14.1) ] . BEQALZI is a BCL-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor. ( 1 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Mechanism: Sonrotoclax is an inhibitor of B-cell lymphoma 2 (BCL-2) protein. Overexpression of BCL-2 in various cancers mediates cell survival and has been associated with chemotherapeutic resistance. Sonrotoclax binds to the BCL-2 protein, displacing pro-apoptotic proteins, thereby inducing apoptosis of cells. In nonclinical studies, sonrotoclax demonstrated cytotoxicity in cancer cells overexpressing BCL-2, with a series of intrinsic apoptotic events, including caspase activation.
Therapeutic areas: Oncology · Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 13, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLetterLabelReview
4 products under this application
- BEQALZI · SONROTOCLAX 20MG · TABLET, ORAL · Prescription
- BEQALZI · SONROTOCLAX 1MG · TABLET, ORAL · Prescription
- BEQALZI · SONROTOCLAX 80MG · TABLET, ORAL · Prescription
- BEQALZI · SONROTOCLAX 5MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sonrotoclax" as an intervention, any sponsor and status, largest first.
- Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)Pivotal-lookingActive, not recruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06073821 · 652 participants (planned) · Start Nov 11, 2023 · Primary completion Feb 2032
Drug: Sonrotoclax; Zanubrutinib and 2 more · For: CLL
Sites: Anchorage, Alaska; Duarte, California; La Jolla, California · 201 sites in all
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06943872 · 630 participants (planned) · Start Jun 11, 2025 · Primary completion Sep 30, 2029
Drug: Sonrotoclax; Obinutuzumab and 2 more · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Laguna Hills, California; Orange, California; Palo Alto, California · 195 sites in all
- A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic LeukemiaPivotal-lookingRecruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT07277231 · 500 participants (planned) · Start Jan 22, 2026 · Primary completion Feb 2031
Drug: Sonrotoclax; Zanubrutinib and 2 more · For: Chronic Lymphocytic Leukemia
Sites: Duarte, California; Orange, California; Palo Alto, California · 115 sites in all
- Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLLPivotal-lookingRecruiting
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT07321652 · 466 participants (planned) · Start Apr 30, 2026 · Primary completion Sep 30, 2028
Drug: Zanubrutinib; Sonrotoclax · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Leukemia
Sites: Birmingham, Alabama; Anaheim, California; Baldwin Park, California · 261 sites in all
- Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell MalignanciesActive, not recruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT04277637 · 437 participants · Start Mar 24, 2020 · Primary completion May 31, 2027
Drug: Sonrotoclax; Zanubrutinib and 1 more · For: Mature B-Cell Malignancies
Sites: Los Angeles, California; Chicago, Illinois; Kansas City, Kansas · 43 sites in all
- A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)Pivotal-lookingRecruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06742996 · 300 participants (planned) · Start Mar 5, 2025 · Primary completion Aug 31, 2028
Drug: Sonrotoclax; Zanubrutinib and 1 more · For: Mantle Cell Lymphoma; B Cell Lymphoma
Sites: Birmingham, Alabama; Tucson, Arizona; Fresno, California · 145 sites in all
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT04771130 · 260 participants (planned) · Start May 24, 2021 · Primary completion Aug 31, 2028
Drug: BGB-11417; Azacitidine and 3 more · For: Acute Myeloid Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasm
Sites: Duarte, California; Tampa, Florida; Pittsburgh, Pennsylvania · 47 sites in all
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06697184 · 258 participants (planned) · Start Jan 23, 2025 · Primary completion Nov 30, 2029
Drug: Sonrotoclax; Zanubrutinib · For: Chronic Lymphocytic Leukemia; CLL; Mantle Cell Lymphoma and 1 more
Sites: Tampa, Florida; Fort Wayne, Indiana; Westwood, Kansas · 22 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use7
- acute kidney injury3
- disease progression3
- myelosuppression3
- white blood cell count decreased3
- neutrophil count decreased2
- pneumonia2
- rhinovirus infection2
- acute myeloid leukaemia1
- adverse event1
- agranulocytosis1
- anaemia1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 6 |
| 2026 | 10 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.
Eyre TA, Song Y, Hermine O, et al. · J Clin Oncol 2026 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Zanubrutinib, obinutuzumab, and venetoclax in CLL: long-term follow up, MRD kinetics, retreatment, T-cell profiling, and PKs.
Soumerai JD, Thompson MC, Dogan A, et al. · Blood Adv 2026 · Clinical Trial, Phase II
Sponsor: BeOne Medicines (BeiGene)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.